| A.P. Pharma, Inc.
(NASDAQ Global Market: APPA) is a specialty pharmaceutical company
focused on the development and commercialization of innovative medical
treatments utilizing its proprietary polymer-based drug delivery systems.
We are a specialty pharmaceutical company focused on developing
pharmaceutical products using our proprietary Biochronomer polymer-based
drug delivery technology. Our product development philosophy is
based on incorporating approved therapeutics into our proprietary
bioerodible drug delivery technology to create controlled release
pharmaceuticals to improve treatments for diseases or conditions.
Our lead product candidate, APF530, is currently in a pivotal Phase
III clinical trial for the prevention of acute and delayed onset
chemotherapy-induced nausea and vomiting, or CINV.
Our primary focus is to advance our proprietary Biochronomer technology,
consisting of bioerodible polymers designed to release drugs over
a defined period. We have completed over 100 in vivo and in vitro
studies demonstrating that our Biochronomer technology is potentially
applicable to a range of therapeutic areas, including pain management,
prevention of nausea and vomiting, control of inflammation and treatment
of ophthalmic diseases. We have also completed comprehensive animal
and human toxicology studies that have established that our Biochronomer
polymers are safe and well tolerated. Furthermore, our Biochronomer
technology can be designed to deliver drugs over periods varying
from days to several months.
Company Strategy
Our primary objective is to be a leading specialty pharmaceutical
company focused on improving the effectiveness of existing pharmaceuticals
using our proprietary drug delivery technologies. Key elements include:
- Expand product pipeline.
- Minimize product development risk and time-to-market.
- Maximize the value of our lead product, APF530.
- Enter into strategic partnerships.
|
 |
